![Sample our Bioscience journals, sign in here to start your access, Latest two full volumes FREE to you for 14 days]({"type":"image" , "src" : "/sda/5925/TOC-Subject-Sample-2021-Bioscience.jpg"})
Abstract
The use of antiepileptic drugs (AEDs) for the treatment of psychiatric disorders has reached a new phase of clinical interest. They are commonly used in the therapy of psychoses, mood disorders, aggression and eating disorders. Pharmacotherapy combinations involving AEDs and antidepressant drugs are used to treat co-morbid psychiatric and neurological disorders, to reduce or control the adverse effects of a medication or to increase a medication effect. Therefore, the impact of pharmacokinetic interactions of this class of drugs is quite relevant. In this paper, the available data about the mechanisms of metabolic kinetic interactions between antidepressant and antiepileptic drugs, as well as their clinical significance, has been reviewed.
Additional information
Notes on contributors
Michael R Trimble
Joyce Laing works in the Department of Child and Family Psychiatry, Playfield House, Cupar, Fife, and is a Consultant Art Therapist to Psychiatric Hospitals and Prisons and Chairwoman of the Scottish Society of Art and Psychology.
Dr Niculescu Dan, Centrul de Reumatologie, Str. J. (F)ucick no. 5, Bucuresti, Romania
Anni Vilppula, Department of Medicine, Paimio Hospital, Preitilä, Finland
G. Tausch, Department of Rheumatology, Municipal Hospital of Vienna-Lainz, Wolkersbergenstraße 1, A-1130Wien, Austria
Dr Guido Gothoni, Medica Pharmaceutical Company Ltd., P.O. Box 325, SF-00101 Helsinki 10, Finland
A. Elman, Dept. of Rheumatology, Karolinska sjukhuset, Stockholm, Sweden
Hannu Paitälä, Rheumatism Foundation Hospital, Heinola, Finland
Jonas Jonsson, National Bacteriological Laboratory, S-105 21 Stockholm, Sweden